Dilated cardiomyopathy is a condition strongly related to heart attacks, in which the ventricles are enlarged, resulting in a thinning of cardiac walls, and insufficient pumping of blood. Dilated cardiomyopathy can occur at any age, though it is most common in the 20-40 demographic. One of the major reasons of dilated cardiomyopathy is genetic. Some other factors that can cause dilated cardiomyopathy are thyroid disorders, viral infections of the heart, diabetes, alcoholism, and heart valve malformations.
Browse Full Global Dilated Cardiomyopathy Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Angiotensin II Receptor Blockers Held Largest Share of Dilated Cardiomyopathy Therapeutics Market in 2013 by Revenue
The dilated cardiomyopathy therapeutics market worldwide is segregated on the basis of drug class, pipeline drugs, and geography. The dilated cardiomyopathy therapeutics market globally in terms of drug class is broadly classified as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, aldosterone antagonists, and angiotensin II receptor blockers (ARBs). Of all the drug class, angiotensin II receptor blockers held the largest share of the dilated cardiomyopathy therapeutics market in 2013 by revenue, followed by beta blockers.
The high demand for the leading drugs for the treatment of dilated cardiomyopathy from developed regions such as Europe and North America is a reason for the large market shares of these classes of drugs. When used in combination either with ACE or ARBs, aldesterone antagonist drugs have proven to have a positive impact on the reduction of progressive conditions such as Duchenne muscular dystrophy (DMD).
The global dilated cardiomyopathy therapeutics market was worth US$651.0 million in 2013. By 2020, the global dilated cardiomyopathy therapeutics market is projected to be worth US$328.6 million which shows a decline of 7% CAGR from...